Sagimet Biosciences
SGMT
8.72
-0.16
-1.80%
Sagimet Biosciences
US · SGMT
#3599 by market cap
Listed 2023
8.72
-0.16
-1.80%
Live - 5344 symbols - heartbeat 335s ago
· 2026-10-08 10:00
Pre-market
8.83
-0.56%
After-hours
8.88
0.00%
- Market cap
- 618.32M
- P/E (TTM)i
- -6.92
- P/Bi
- 2.41
- EPSi
- -1.58
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on SGMT?
Anonymous reader poll. Unscientific, not investment advice.
About Sagimet Biosciences
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
- Founded
- 2006
- CEO
- Mr. David Happel
- Employees
- 16
- Headquarters
- San Mateo, California, United States of America
- Fiscal year end
- 12-31
- Website
- sagimet.com
Company profile
- Exchange
- US
- Symbol
- SGMT
- Market-cap rank
- #3599
- Listing date
- 2023-07-14
- Market cap
- 618.32M
- Float cap
- 562.71M
- Shares out
- 70.91M
- Float shares
- 64.53M
Sectors & themes
Quote time 2026-10-08 10:00:18 · For reference only, not investment advice and not tailored to your situation.